Trump’s New Drug Price Order: Korean Biotech’s $4 Billion Opportunity
The pharmaceutical landscape is set for a dramatic shift as President Donald Trump takes aim at prescription drug pricing through a sweeping executive order signed on April 15, 2025. This move specifically elevates biosimilars—lower-cost alternatives to biological medications—into a position of regulatory preference. The policy shift represents not just a domestic healthcare reform, but potentially…